ClinicalTrials.gg
Sign In
CompletedNCT04693351Updated May 22, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder

A Phase 3 interventional study of Troriluzole and Placebo in Obsessive-Compulsive Disorder, sponsored by Biohaven Pharmaceuticals, Inc.. Completed at 89 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Biohaven Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
589
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study was to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in participants with Obsessive Compulsive Disorder (OCD).

02

Conditions studied

  • Obsessive-Compulsive Disorder

Keywords

  • Obsessive-Compulsive Disorder (OCD)
03

In context

Obsessive-Compulsive Disorder

635 studies on the registry are indexed under Obsessive-Compulsive Disorder; 166 are open to participants now.

This study's enrollment of 589 is above the median of 45 across 520 interventional studies indexed under Obsessive-Compulsive Disorder.

Browse Obsessive-Compulsive Disorder studies →

Lead sponsor

Biohaven Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 6 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Primary diagnosis of OCD as per , Fifth Edition as confirmed by the Mini International Neuropsychiatric Interview (MINI) at screening; the duration of the participants illness must be ≥ 1year
  2. An inadequate response to current standard of care (SOC) medication defined as selective serotonin reuptake inhibitor (excluding fluvoxamine) or clomipramine treatment at an adequate and stable dose for at least 8 weeks prior to screening and at least 12 weeks at baseline (adequate dose defined by US Package Insert [USPI] labelling); an inadequate response to current SOC based on the Yale-Brown Obsessive Compulsive Scale (YBOCS) score.
  3. Determined by the investigator to be medically stable at baseline/ randomization as assessed by medical history, physical examination, laboratory test results, and testing. Participants must be physically able and expected to complete the trail as designed.

Key Exclusion Criteria:

  1. Participants with a history of more than two (2) previous failed or inadequate treatment classes given for an adequate duration at an adequate dose as defined by the Massachusetts General Hospital Treatment Response Questionnaire for OCD (MGH-TRQ-OCD).
  2. Current or prior history of bipolar I or II disorder, schizophrenia or other psychotic disorders, schizoaffective disorder, autism or autism spectrum disorders, borderline personality disorder, antisocial personality disorder, Tourette's disorder, body dysmorphic disorder, hoarding disorder, or psychosurgery, Deep Brain Stimulation (DBS) or Electroconvulsive Therapy (ECT); or general medical condition that may confound safety and/or efficacy results.
  3. Previous treatment in a study with troriluzole.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
589 participants (actual)

Study arms

  • Experimental
    Troriluzole

    Participants received troriluzole 200 milligrams (mg) (100 mg\*2) capsules orally once daily for the first two weeks and up-titrated to 280 mg (140 mg\*2) capsules orally once daily for the next eight weeks, in the double-blind randomization phase.

    Drug: Troriluzole

  • Placebo comparator
    Placebo

    Participants received placebo-matched to troriluzole capsules orally once daily for 10 weeks of the double-blind randomization phase.

    Drug: Placebo

Interventions

  • DrugTroriluzole

    Capsules for oral administration.

  • DrugPlacebo

    Drug- matching capsules for oral administration.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement)

    Y-BOCS was a clinician-administered instrument used to assess the severity of obsessive compulsive disorder (OCD) symptoms and to monitor treatment response. The scale included 10 items: 5 items assessed obsessions and 5 items assessed compulsions. Each item was rated from 0 to 4, generating an obsessions subscale score (0-20), a compulsions subscale score (0-20), and a total score ranging from 0 to 40. Higher scores indicated greater OCD symptom severity. Negative change (or reduction in score) indicates improvement.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An Adverse event (AE) was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant, that did not necessarily have a causal relationship with treatment. An AE could be any unfavourable/unintended sign including an abnormal laboratory finding, symptom/disease temporally associated with the use of the study drug, whether or not considered related to it. A TEAE was defined as any AE that developed, worsened, or became serious after first dose of test treatment

    Time frame: From first dose up to approximately 12 weeks

  2. Change From Baseline in Sheehan Disability Scale (SDS) Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8

    The SDS was a participant-rated measure of functional disability. SDS was assessed in 3 domains: work/school (0-10), social life (0-10), and family life (0-10). The score from each domain was summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). Higher scores indicated a more severe impairment.

    Time frame: Baseline and Week 8

  3. Change From Baseline in Clinical Global Impression of Severity (CGI-S) Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8

    The CGI-S was a clinician rated assessment of the participants current illness state on a 7-point scale. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Higher scores indicated a more severe illness.

    Time frame: Baseline and Week 8

Other outcomes

  1. Change From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS = 22 or 23 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement)

    Y-BOCS was a clinician-administered instrument used to assess the severity of obsessive compulsive disorder (OCD) symptoms and to monitor treatment response. The scale included 10 items: 5 items assessed obsessions and 5 items assessed compulsions. Each item was rated from 0 to 4, generating an obsessions subscale score (0-20), a compulsions subscale score (0-20), and a total score ranging from 0 to 40. Higher scores indicated greater OCD symptom severity. Negative change (or reduction in score) indicates improvement.

    Time frame: Baseline and Week 8

07

Results

Posted May 22, 2026

Participant flow

A total 589 participants were randomized, and 581 participants received at least one dose of study treatment. The study was conducted at multiple sites in the United States, United Kingdom, China and Europe.

Participant flow — Overall Study
MilestoneTroriluzolePlacebo
Started294295
Treated292289
Y-bocs score >=24 cohort259257
Y-bocs score 22-23 cohort3538
Completed256258
Not completed3837
Withdrew: Adverse event129
Withdrew: Lack of efficacy11
Withdrew: Non-compliance02
Withdrew: Protocol violation02
Withdrew: Withdrawal by subject1714
Withdrew: Lost to follow-up67
Withdrew: Miscellaneous22

Outcome measures

PrimaryChange From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement)

Y-BOCS was a clinician-administered instrument used to assess the severity of obsessive compulsive disorder (OCD) symptoms and to monitor treatment response. The scale included 10 items: 5 items assessed obsessions and 5 items assessed compulsions. Each item was rated from 0 to 4, generating an obsessions subscale score (0-20), a compulsions subscale score (0-20), and a total score ranging from 0 to 40. Higher scores indicated greater OCD symptom severity. Negative change (or reduction in score) indicates improvement.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement)
score on a scaleTroriluzolePlacebo
Change From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement)-3.62 ± 0.446-4.59 ± 0.454
Statistical analysis
  • Troriluzole vs Placebo · Mixed Models Analysis · p = 0.041 (The primary endpoint was tested at a two-sided alpha (p\<0.0455) per the O'Brien-Fleming spending function. If significant, secondary endpoints were tested using Pocock alpha spending and Hochberg's procedure. This was done to control type 1 error.) · Least squares mean difference: 0.97 · 95% CI 0.02 to 1.92Confidence interval was based on repeated confidence interval method described by Jennison and Turnbull.
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An Adverse event (AE) was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant, that did not necessarily have a causal relationship with treatment. An AE could be any unfavourable/unintended sign including an abnormal laboratory finding, symptom/disease temporally associated with the use of the study drug, whether or not considered related to it. A TEAE was defined as any AE that developed, worsened, or became serious after first dose of test treatment

Time frame:
From first dose up to approximately 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsTroriluzolePlacebo
Number of Participants With Treatment Emergent Adverse Events (TEAEs)199172
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8

The SDS was a participant-rated measure of functional disability. SDS was assessed in 3 domains: work/school (0-10), social life (0-10), and family life (0-10). The score from each domain was summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). Higher scores indicated a more severe impairment.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8
score on a scaleTroriluzolePlacebo
Change From Baseline in Sheehan Disability Scale (SDS) Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8-2.47 ± 0.530-3.57 ± 0.538
Statistical analysis
  • Troriluzole vs Placebo · Mixed Models Analysis · p = 0.054 (A hierarchical testing strategy was used for error control. Secondary endpoints were tested only if the primary endpoint was significant. The Hochberg procedure was applied using a two-sided alpha of 0.0243 based on a Pocock-style spending function.) · Least squares mean difference: 1.10 · 95% CI -0.19 to 2.39Confidence interval based on repeated confidence interval method described by Jennison and Turnbull.
SecondaryChange From Baseline in Clinical Global Impression of Severity (CGI-S) Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8

The CGI-S was a clinician rated assessment of the participants current illness state on a 7-point scale. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Higher scores indicated a more severe illness.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8
score on a scaleTroriluzolePlacebo
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8-0.38 ± 0.068-0.49 ± 0.069
Statistical analysis
  • Troriluzole vs Placebo · Mixed Models Analysis · p = 0.148 (A hierarchical testing strategy was used for error control. Secondary endpoints were tested only if the primary endpoint was significant. The Hochberg procedure was applied using a two-sided alpha of 0.0243 based on a Pocock-style spending function.) · Least squares mean difference: 0.11 · 95% CI -0.06 to 0.27Confidence interval based on repeated confidence interval method described by Jennison and Turnbull.
Other pre-specifiedChange From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS = 22 or 23 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement)

Y-BOCS was a clinician-administered instrument used to assess the severity of obsessive compulsive disorder (OCD) symptoms and to monitor treatment response. The scale included 10 items: 5 items assessed obsessions and 5 items assessed compulsions. Each item was rated from 0 to 4, generating an obsessions subscale score (0-20), a compulsions subscale score (0-20), and a total score ranging from 0 to 40. Higher scores indicated greater OCD symptom severity. Negative change (or reduction in score) indicates improvement.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS = 22 or 23 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement)
score on a scaleTroriluzolePlacebo
Change From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS = 22 or 23 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement)-3.81 ± 1.441-4.20 ± 1.339
Statistical analysis
  • Troriluzole · Mixed Models Analysis · p = 0.796 · Least squares mean difference: 0.39 · 95% CI -2.62 to 3.41

Adverse events

Collected over For Adverse Events: From first dose up to approximately 12 weeks For All-cause Mortality: From Day 1 up to approximately 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Troriluzole0/294 (0%)3/292 (1%)116/292 (39.7%)
Placebo0/295 (0%)2/289 (0.7%)85/289 (29.4%)
Most frequent serious events
Most frequent serious events
EventTroriluzolePlacebo
PneumoniaInfections and infestations0/2921/289
Lower limb fractureInjury, poisoning and procedural complications0/2921/289
Obsessive-compulsive disorderPsychiatric disorders1/2920/289
Panic attackPsychiatric disorders1/2920/289
HaemorrhoidsGastrointestinal disorders1/2920/289
Most frequent other events
Most frequent other events
EventTroriluzolePlacebo
NauseaGastrointestinal disorders42/29224/289
HeadacheNervous system disorders41/29238/289
FatigueGeneral disorders27/29226/289
DizzinessNervous system disorders25/29211/289
NasopharyngitisInfections and infestations15/29210/289
Upper respiratory tract infectionInfections and infestations15/2929/289

Baseline characteristics

Safety Population included enrolled participants who received at least one dose of blinded study therapy (troriluzole or placebo).

Age, Continuous
Age, Continuous(years)TroriluzolePlaceboTotal
Mean37.0 ± 12.6936.8 ± 12.9436.9 ± 12.81
Sex: Female, Male
Sex: Female, Male(Participants)TroriluzolePlaceboTotal
Female184187371
Male108102210
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TroriluzolePlaceboTotal
Hispanic or Latino363066
Not Hispanic or Latino237245482
Unknown or Not Reported191433
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TroriluzolePlaceboTotal
Asian5851109
Black or African American121426
White215211426
Other51116
Not Reported224
Baseline (YBOCS) total score
Baseline (YBOCS) total score(units on a scale)TroriluzolePlaceboTotal
Mean27.5 ± 3.6227.6 ± 3.5227.5 ± 3.57
08

Study locations

89 sites
  • Alea Research
    Phoenix, Arizona 85012, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Kaizen Brain Center
    La Jolla, California 92037, United States
  • Om Research LLC
    Lancaster, California 93534, United States
  • CalNeuro Research Group
    Los Angeles, California 90024, United States
  • Lumos Clinical Research Center, LLC
    San Jose, California 95124, United States
  • Velocity Clinical Research
    Santa Ana, California 92704, United States
  • California Neuroscience Research Medical Group, Inc.
    Sherman Oaks, California 91403, United States
  • Pacific Clinical Research Medical Group
    Upland, California 91786, United States
  • Mountain View Clinical Research
    Denver, Colorado 80209, United States
  • Comprehensive Psychiatric Care
    Norwich, Connecticut 06360, United States
  • Topaz Clinical Research
    Apopka, Florida 32703, United States
  • CNS Research of Coral Springs
    Coral Springs, Florida 33067, United States
  • Gulfcoast Clinical Research Center
    Fort Myers, Florida 33912, United States
  • University of Florida Department of Psychiatry
    Gainesville, Florida 32606, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Med-Care Research
    Miami, Florida 33165, United States
  • Ezy Medical Research, Co.
    Miami, Florida 33175, United States
  • Advanced Research for Health Improvement
    Naples, Florida 34102, United States
  • Harmony Clinical Research
    North Miami Beach, Florida 33162, United States
  • dTMS Center LLC
    Palm Beach, Florida 33480, United States
  • DMI Research
    Pinellas Park, Florida 33782, United States
  • CenExel iResearch
    Decatur, Georgia 30030, United States
  • Renew Health Clinical Research, LLC
    Snellville, Georgia 30078, United States
  • University of Chicago Department of Psychiatry & Behavioral Neuroscience
    Chicago, Illinois 60637, United States
  • AMR-Baber Research, Inc.
    Naperville, Illinois 60563, United States
  • Collective Medical Research
    Overland Park, Kansas 66210, United States
  • Continental Clinical Solutions, LLC
    Towson, Maryland 21204, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Psychiatric Care and Research Center
    O'Fallon, Missouri 63368, United States
  • Boeson Research
    Missoula, Montana 59804, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey 08028, United States
  • SPRI Clinical Trials, LLC
    Brooklyn, New York 11235, United States
  • Manhattan Behavioral Medicine, PLLC
    New York, New York 10036, United States
  • Richard H. Weisler, MD PA & Associates
    Raleigh, North Carolina 27609, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • American Clinical Research Institute (ACRI)
    Dayton, Ohio 45432, United States
  • American Research Institute (ACRI)
    Kettering, Ohio 45439, United States
  • North Star Medical Research, LLC
    Middleburg Heights, Ohio 44130, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Donald J. Garcia Jr., MD PA
    Austin, Texas 78737, United States
  • Inquest Clinical Research
    Baytown, Texas 77521, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • InSite Clinical Research
    DeSoto, Texas 75115, United States
  • Clinical Trial Network
    Houston, Texas 77074, United States
  • AIM Trials
    Plano, Texas 75093, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Woodstock Research Center
    Woodstock, Vermont 05091, United States
  • University of Calgary
    Calgary, Alberta T2N 4Z6, Canada
  • Chatham-Kent Clinical Trials Research Centre
    Chatham, Ontario N7L 1C1, Canada
  • McMaster University, Hamilton Health Sciences
    Hamilton, Ontario L8S 1B7, Canada
  • Queen's University
    Kingston, Ontario K7L 5G2, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • START Clinic for Mood and Anxiety Disorders
    Toronto, Ontario M4W 2N4, Canada
  • University of Toronto / Centre for Addiction and Mental Health (CAMH)
    Toronto, Ontario M6J 1H4, Canada
  • Beijing HuiLongGuan Hospital
    Beijing, Changping District 100085, China
  • Peking University Sixth Hospital
    Beijing, Haidian District 100083, China
  • Hangzhou Seventh People's Hospital
    Hangzhou, Hangzhou City 310063, China
  • Tianjin Anding Hospital
    Tianjin, Hexi District 300222, China
  • The Second Xiangya Hospital of Central South University
    Xiangya, Hunan 410008, China
  • Nanjing Brain Hospital
    Nanjing, Jiangsu 210029, China
  • Shanghai Mental Health Center
    Shanghai, Minhang District 201108, China
  • Wuhan Mental Health Center
    Wuhan, Qiaokou District 430022, China
  • The First Affiliated Hospital of Jinan University
    Guangzhou, Tianhe District 510660, China
  • Mental Health Center, West China Hospital, Sichuan University
    Chengdu, Wuhou District 610041, China
  • First Hospital of Hebei Medical University
    Shijiazhuang, Yuhua District 050001, China
  • ASST FBF SACCO - Ospedale Universitario Luigi Sacco
    Milan, 20157, Italy
  • University School of Medicine of Napoli Federico II
    Naples, 80131, Italy
  • University of Pisa
    Pisa, 56126, Italy
  • University of Turin - university hospital san luigi gonzaga
    Turin, 10043, Italy
  • Amsterdam UMC, locatie AMC
    Amsterdam, 1100, Netherlands
  • Leiden University Medical Center (LUMC)
    Leiden, 2333, Netherlands
  • Hospital Universitario de Bellvitge
    Barcelona, 08907, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital Clínico San Carlos
    Madrid, 28040, Spain
  • Centro de Salud Mental La Corredoria
    Oviedo, 33011, Spain
  • Centro de Salud San Juan
    Salamanca, 37005, Spain
  • Hospital Álvaro Cunqueiro
    Vigo, 36312, Spain
  • MAC Clinical Research
    Stockton-on-Tees, County Durham TS17 6EW, United Kingdom
  • Stemax Consult - Healthcare Services Ltd
    Stony Stratford, Northamptonshire MK19 6FG, United Kingdom
  • MAC Clinical Research - South Staffordshire
    Cannock, South Staffordshire WS11 0BN, United Kingdom
  • MAC Clinical Research-Lancashire
    Blackpool, FY2 0JH, United Kingdom
  • MAC Clinical Research
    Leeds, LS10 1DU, United Kingdom
  • MAC Clinical Research -- Merseyside
    Liverpool, L34 1BH, United Kingdom
  • Greater Manchester Mental Health NHS Foundation Trust
    Manchester, M25 3BL, United Kingdom
  • Bioluminux Ltd
    Milton Keynes, MK15 0DU, United Kingdom
  • Kingshill Research Centre
    Swindon, SN3 6BW, United Kingdom
  • MAC Clinical Research-- South Yorkshire
    Tankersley, S75 3DL, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04693351
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jan 5, 2021
Start date
Jan 29, 2021
Primary completion
Apr 29, 2025
Completion
Apr 29, 2025
Results posted
May 22, 2026
Last update
May 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Troriluzole

Other studies in this condition

Obsessive-Compulsive Disorder →

Other studies from this sponsor

Biohaven Pharmaceuticals, Inc.

Start the discussion